On January 13, 2021, Inhibrx, Inc. announced the U.S. Food and Drug Administration has granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. INBRX-109 is a precisely engineered tetravalent single domain antibody-based therapeutic candidate that agonizes death receptor 5 (DR5) to induce tumor selective programmed cell death.